Stephen F. Thompson

Statistics

Publications

Citations

342

H-Index

Active since

2004

Affiliations

Teva Pharmaceuticals (United States)(Current)

Teva Pharmaceuticals (Netherlands)

Analysis Group (United States)

Stephen F. Thompson is an author at Teva Pharmaceuticals (United States) specializing in migraine pharmacotherapy, pharmacotherapy, and preventive migraine treatment.

Publications per year

2004–2022

Publications

Rhinitis therapy and the prevention of hospital care for asthma

Jonathan Corren, Beatrice E. Manning, Stephen F. Thompson et al. · Journal of Allergy and Clinical Immunology · 2004 · 212 citations

Life Sciences, Clinical Sciences, Allergy +13

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson et al. · The Journal of Headache and Pain · 2022 · 44 citations · Full text

Medicine, Neurology, Pharmacotherapy +16

Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System

Stephen D. Silberstein, Shoshana Reshef, Joshua M. Cohen et al. · Advances in Therapy · 2022 · 41 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

Lynda J. Krasenbaum, V. Pedarla, Stephen F. Thompson et al. · The Journal of Headache and Pain · 2022 · 23 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson‐Lomba et al. · The Journal of Headache and Pain · 2022 · 22 citations · Full text

Medicine, Neurology, Pharmacotherapy +16

1–5 of 5